Kantonsspital St.Gallen
login

publications

Lukas Flatz

title  
 
Berner F, Bomze D, Diem S, Ali O H, Fässler M, Ring S, Niederer R, Ackermann C J, Baumgaertner P, Pikor N, Gil Cruz C, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng H W, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A N, Jochum W, Speiser D E, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019;.
   
Gil Cruz C, Perez Shibayama C, De Martin A, Ronchi F, van der Borght K, Niederer R, Onder L, Lütge M, Novkovic M, Nindl V, Ramos G, Arnoldini M, Slack E M C, Boivin-Jahns V, Jahns R, Wyss M, Mooser C, Lambrecht B N, Maeder M T, Rickli H, Flatz L, Eriksson U, Geuking M B, McCoy K D, Ludewig B. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. Science 2019; 366:881-886.
   
Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Perez Shibayama C, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D E, Ludewig B, Levesque M P, Dummer R, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer 2019; 7:50.
   
Trefny M P, Rothschild S I, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M A, Berner F, Kashyap A S, Kaiser M, Herzig P, Poechtrager S, Thommen D S, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K D, Zippelius A, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clin Cancer Res 2019; 25:3026-3034.
   
Isak V, Beerli T, Cozzio A, Flatz L. A Rare Case of Localized Argyria on the Face. Case Rep Dermatol 2019; 11:23-27.
   
Diem S, Fässler M, Bomze D, Ali O H, Berner F, Niederer R, Hillmann D, Mangana J, Levesque M P, Dummer R, Risch L, Recher M, Risch M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. J Immunother 2019; 42:89-93.
   
Berner F, Bomze D, Flatz L. Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply. JAMA Oncol 2019;.
   
Fischer S, Ali O H, Jochum W, Kluckert J T, Flatz L, Siano M. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. Oncol Res Treat 2018; 41:391-394.
   
Hartwig T, Zwicky P, Schreiner B, Yawalkar N, Cheng P, Navarini A, Dummer R, Flatz L, Conrad C, Schlapbach C, Becher B. Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. Cell Rep 2018; 25:3564-3572.e4.
   
Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, Joerger M, Früh M, Driessen C, Lenz T L, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2018; 107:8-14.
   
Schmid S, Diem S, Li Q, Krapf M, Flatz L, Leschka S, Desbiolles L, Klingbiel D, Jochum W, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother 2018;.
   
Diem S, Fässler M, Ali O H, Siano M, Niederer R, Berner F, Roux G A, Ackermann C J, Schmid S, Güsewell S, Früh M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018; 10:5537-5544.
   
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A J, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017; 111:176-181.
   
Remy M M, Sahin M, Flatz L, Regen T, Xu L, Kreutzfeldt M, Fallet B, Doras C, Rieger T, Bestmann L, Hanisch U K, Kaufmann B A, Merkler D, Pinschewer D D. Interferon-γ-Driven iNOS: A Molecular Pathway to Terminal Shock in Arenavirus Hemorrhagic Fever. Cell Host Microbe 2017; 22:354-365.e5.
   
Diem S, Hasan Ali O, Ackermann C J, Bomze D, Koelzer V H, Jochum W, Speiser D E, Mertz K D, Flatz L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunol Immunother 2017; 67:39-45.
   
Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra A A, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle P A, Wollmann G, von Laer D, Drexler I, Rathbun J, Cannon P M, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang P A, Lang K S. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun 2017; 8:14447.
   
Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman A J, Müller J, Flatz L. GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography. JAAD Case Rep 2016; 2:415-417.
   
Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L E, Speiser D E, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 2016; 5:e1231292.
   
Diem S, Keller F, Rüesch R, Maillard S A, Speiser D E, Dummer R, Siano M, Urner-Bloch U, Goldinger S M, Flatz L, Diem S. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. J Immunother 2016; 39:379-382.
   
Ring S, Flatz L. Generation of Lymphocytic Choriomeningitis Virus Based Vaccine Vectors. Methods Mol Biol 2016; 1404:351-64.
   
Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC Cancer 2016; 16:656.
   
Sommerstein R, Flatz L, Remy M M, Malinge P, Magistrelli G, Fischer N, Sahin M, Bergthaler A, Igonet S, Ter Meulen J, Rigo D, Meda P, Rabah N, Coutard B, Bowden T A, Lambert P H, Siegrist C A, Pinschewer D D. Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLoS Pathog 2015; 11:e1005276.
   
Johnson S, Bergthaler A, Graw F, Flatz L, Bonilla W V, Siegrist C A, Lambert P H, Regoes R R, Pinschewer D D. Protective efficacy of individual CD8+ T cell specificities in chronic viral infection. J Immunol 2015; 194:1755-62.
   
Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, Gaide O, Michielin O, Hwu P, Petrova T V, Martinon F, Modlin R L, Speiser D E, Gilliet M. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci USA 2015; 112:15408-13.
   
Bhattacharya A, Hegazy A N, Deigendesch N, Kosack L, Cupovic J, Kandasamy R K, Hildebrandt A, Merkler D, Kühl A A, Vilagos B, Schliehe C, Panse I, Khamina K, Baazim H, Arnold I, Flatz L, Xu H C, Lang P A, Aderem A, Takaoka A, Superti-Furga G, Colinge J, Ludewig B, Löhning M, Bergthaler A. Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage. Immunity 2015; 43:974-86.
   
Sommerstein R, Ramos da Palma J, Olschläger S, Bergthaler A, Barba L, Lee B P L, Pasquato A, Flatz L. Evolution of Recombinant Lymphocytic Choriomeningitis Virus/Lassa Virus In Vivo Highlights the Importance of the GPC Cytosolic Tail in Viral Fitness. J Virol 2014; 88:8340-8348.
   
Roychoudhuri R, Lefebvre F, Honda M, Pan L, Ji Y, Klebanoff C A, Nichols C N, Fourati S, Hegazy A N, Goulet J P, Gattinoni L, Nabel G J, Gilliet M, Cameron M, Restifo N P, Sékaly R P, Flatz L. Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation. Vaccine 2014; 33:914-23.
   
Speiser D E, Flatz L. Cancer immunotherapy drives implementation science in oncology. Hum Vaccin Immunother 2014; 10:3107-10.
   
Clayton H, Flatz L, Vollenweider-Roten S, Schoepfer A, Gilliet M, Conrad C. Anti-TNF therapy in the treatment of psoriasis in a patient with acute-on-chronic pancreatitis. Dermatology (Basel) 2013; 227:193-6.
   
Flatz L, Conrad C. Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy. Psoriasis: Targets & Therapy 2013;.
   
Olschläger S, Flatz L. Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials. PLoS Pathog 2013; 9:e1003212.
   
Flatz L, Cheng C, Wang L, Foulds K E, Ko S Y, Kong W P, Roychoudhuri R, Shi W, Bao S, Todd J P, Asmal M, Shen L, Donaldson M, Schmidt S D, Gall J G D, Pinschewer D D, Letvin N L, Rao S, Mascola J R, Roederer M, Nabel G J. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J Virol 2012; 86:7760-70.
   
Zürcher S, Mooser C, Lüthi A U, Mühlemann K, Barbani M T, Mohacsi P, Garzoni C, Gorgievski-Hrisoho M, Schaller A, Flatz L. Sensitive and rapid detection of ganciclovir resistance by PCR based MALDI-TOF analysis. J Clin Virol 2012; 54:359-63.
   
Kerber R, Rieger T, Busch C, Flatz L, Pinschewer D D, Kümmerer B M, Günther S. Cross-species analysis of the replication complex of Old World arenaviruses reveals two nucleoprotein sites involved in L protein function. J Virol 2011; 85:12518-28.
   
Flatz L, Roychoudhuri R, Honda M, Filali-Mouhim A, Goulet J P, Kettaf N, Lin M, Roederer M, Haddad E K, Sékaly R P, Nabel G J. Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines. Proc Natl Acad Sci USA 2011; 108:5724-9.
   
Hegazy A N, Peine M, Helmstetter C, Panse I, Fröhlich A, Bergthaler A, Flatz L, Pinschewer D D, Radbruch A, Löhning M. Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions. Immunity 2010; 32:116-28.
   
Pinschewer D D, Flatz L, Steinborn R, Horvath E, Fernandez M, Lutz H, Suter M, Bergthaler A. Innate and adaptive immune control of genetically engineered live-attenuated arenavirus vaccine prototypes. Int Immunol 2010; 22:749-56.
   
Bergthaler A, Flatz L, Hegazy A N, Johnson S, Horvath E, Löhning M, Pinschewer D D. Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression. Proc Natl Acad Sci USA 2010; 107:21641-6.
   
Flatz L, Rieger T, Merkler D, Bergthaler A, Regen T, Schedensack M, Bestmann L, Verschoor A, Kreutzfeldt M, Brück W, Hanisch U K, Günther S, Pinschewer D D. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog 2010; 6:e1000836.
   
Flatz L, Hegazy A N, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, Broek M v d, Radbruch A, Lévy F, Lambert P H, Siegrist C A, Restifo N P, Löhning M, Ochsenbein A F, Nabel G J, Pinschewer D D. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med 2010; 16:339-45.
   
Bergthaler A, Flatz L, Verschoor A, Hegazy A N, Holdener M, Fink K, Eschli B, Merkler D, Sommerstein R, Horvath E, Fernandez M, Fitsche A, Senn B M, Verbeek J S, Odermatt B, Siegrist C A, Pinschewer D D. Impaired antibody response causes persistence of prototypic T cell-contained virus. PLoS Biol 2009; 7:e1000080.
   
Heikenwalder M, Prinz M, Zeller N, Lang K S, Junt T, Rossi S, Tumanov A, Schmidt H, Priller J, Flatz L, Rülicke T, Macpherson A J, Holländer G A, Nedospasov S A, Aguzzi A. Overexpression of lymphotoxin in T cells induces fulminant thymic involution. Am J Pathol 2008; 172:1555-70.
   
Navarini A A, Recher M, Lang K S, Georgiev P, Meury S, Bergthaler A, Flatz L, Bille J, Landmann R, Odermatt B, Hengartner H, Zinkernagel R M. Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. Proc Natl Acad Sci USA 2006; 103:15535-9.
   
Flatz L, Bergthaler A, de la Torre J C, Pinschewer D D. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc Natl Acad Sci USA 2006; 103:4663-8.
   
Flatz L, Cottagnoud M, Kühn F, Entenza J, Stucki A, Cottagnoud P. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci. J Antimicrob Chemother 2004; 53:305-10.
   
Cottagnoud P, Pfister M, Acosta F, Cottagnoud M, Flatz L, Kühn F, Müller H P, Stucki A. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004; 48:3928-33.
   
Kühn F, Cottagnoud M, Acosta F, Flatz L, Entenza J, Cottagnoud P. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro. Antimicrob Agents Chemother 2003; 47:2487-91.
   
Cottagnoud P, Cottagnoud M, Acosta F, Flatz L, Kühn F, Stucki A, Entenza J. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis. Eur J Clin Microbiol Infect Dis 2003; 22:656-62.
   
 
page 1 of 1